TB-500 — its name, research and unanswered questions

What is TB-500?

In the FDA's 2026 assessment, TB-500 means a synthetic fragment of thymosin beta-4 consisting of seven amino acids. Full-length thymosin beta-4 is a different, longer molecule. The names may sound similar, but should not be used interchangeably. [31]

The issue is complicated by sellers not always using the name TB-500 consistently. A 2012 analytical study identified a particular fragment in a specific preparation. That finding describes the contents of that sample, not every product sold today under a similar name. [32]

Why the association with tissue repair?

Full-length thymosin beta-4 has been studied in tissue healing, among other areas. One example is RGN-259 eye drops, assessed in patients with a rare corneal disease. This was not an experiment with the TB-500 fragment administered for a muscle or tendon injury. [34]

A fragment of a larger molecule may retain some of its properties, but this cannot be assumed without investigation. It may reach tissues differently, remain in the body for a shorter or longer time and have different adverse effects. Structural similarity identifies a research question; it does not replace the results.

Has effective recovery been demonstrated in humans?

In a review prepared for a July 2026 meeting, the FDA found no clinical studies that could assess TB-500's effectiveness in humans. It also identified major safety research gaps. There is therefore no basis for presenting it as an established method of wound healing or injury treatment. [31]

Insufficient evidence does not prove that an idea will never work. It means that we cannot currently define its expected benefits and risks reliably. This is an important distinction for someone comparing an experimental substance with a treatment whose uses are well described.

Is the label alone enough?

Analysis of TB500/TB1000 products bought online found differences between their contents and earlier descriptions. This does not mean every product is counterfeit. It does show why a commercial name does not establish a substance's identity. [33]

This also complicates accounts of effects: if a preparation's contents are unknown, its effects cannot be attributed confidently. A sound study should clearly define the composition and quality of the product tested.

What do we know about risks and status?

Uncertainty about a substance's safety and uncertainty about a product's quality are two different problems. Australia's regulator, the TGA, lists TB-500 among unapproved peptide products and warns about risks including composition and sterility. This statement concerns Australia. [53]

In the US, TB-500 was included in the October draft policy concerning certain compounded preparations. This is not drug approval or evidence that it treats injuries. [51] [52]

What are the rules in sport?

The 2026 WADA list includes thymosin beta-4 and its derivatives, such as TB-500, in section S2.3. They are prohibited both in and out of competition. A sporting ban does not establish medical effectiveness. [54]

Where do we compare study types?

TB-500: why does the substance's name matter? — we use an eye study to explain how to avoid misleading conclusions.

Where does this information come from?